Alina S Gerrie

Summary

Affiliation: British Columbia
Country: Canada

Publications

  1. doi Chemoresistance can be overcome with high-dose chemotherapy and autologous stem-cell transplantation for relapsed and refractory Hodgkin lymphoma
    A S Gerrie
    Leukemia Bone Marrow Transplant Program of British Columbia and the Division of Hematology, British Columbia Cancer Agency and the University of British Columbia Center for Lymphoid Cancer Research and the Division of Medical Oncology, British Columbia Cancer Agency and the University of British Columbia, Vancouver, Canada
    Ann Oncol 25:2218-23. 2014
  2. doi D(T)PACE as salvage therapy for aggressive or refractory multiple myeloma
    Alina S Gerrie
    Hematology, University of British Columbia, Vancouver, BC, Canada
    Br J Haematol 161:802-10. 2013
  3. doi Oral fludarabine and rituximab as initial therapy for chronic lymphocytic leukemia or small lymphocytic lymphoma: population-based experience matches clinical trials
    Alina S Gerrie
    Division of Hematology, University of British Columbia, Vancouver, BC, Canada
    Leuk Lymphoma 53:77-82. 2012
  4. doi Fludarabine and rituximab for relapsed or refractory hairy cell leukemia
    Alina S Gerrie
    Division of Hematology, University of British Columbia, 2775 Laurel St, Vancouver, BC, Canada
    Blood 119:1988-91. 2012
  5. doi Influence of clone and deletion size on outcome in chronic lymphocytic leukemia patients with an isolated deletion 13q in a population-based analysis in British Columbia, Canada
    Steven J T Huang
    Leukemia BMT Program of BC, Vancouver General Hospital and British Columbia Cancer Agency, University of British Columbia, Vancouver, BC, Canada
    Genes Chromosomes Cancer 55:16-24. 2016
  6. doi Impact of time from diagnosis to initiation of curative-intent chemotherapy on clinical outcomes in patients with classical Hodgkin lymphoma
    Edward G Brooks
    a Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada
    Leuk Lymphoma 57:872-9. 2016
  7. doi Population-based characterization of the genetic landscape of chronic lymphocytic leukemia patients referred for cytogenetic testing in British Columbia, Canada: the role of provincial laboratory standardization
    Alina S Gerrie
    Leukemia BMT Program of BC, Vancouver General Hospital and British Columbia Cancer Agency, University of British Columbia, Vancouver, Canada
    Cancer Genet 207:316-25. 2014
  8. doi Rituximab with high-dose methotrexate in primary central nervous system lymphoma
    Roopesh Kansara
    Centre for Lymphoid Cancer and Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    Am J Hematol 90:1149-54. 2015
  9. doi Allogeneic Hematopoietic Stem Cell Transplantation Is an Effective Salvage Therapy for Patients with Chronic Myeloid Leukemia Presenting with Advanced Disease or Failing Treatment with Tyrosine Kinase Inhibitors
    Anish P Nair
    Leukemia BMT Program of British Columbia, Division of Hematology, Vancouver General Hospital, British Columbia Cancer Agency, and University of British Columbia, Vancouver, British Columbia, Canada
    Biol Blood Marrow Transplant 21:1437-44. 2015
  10. doi Immunoglobulin heavy chain (IGH@) translocations negatively impact treatment-free survival for chronic lymphocytic leukemia patients who have an isolated deletion 13q abnormality
    Alina S Gerrie
    Division of Hematology, University of British Columbia, Vancouver, Canada
    Cancer Genet 205:523-7. 2012

Collaborators

Detail Information

Publications12

  1. doi Chemoresistance can be overcome with high-dose chemotherapy and autologous stem-cell transplantation for relapsed and refractory Hodgkin lymphoma
    A S Gerrie
    Leukemia Bone Marrow Transplant Program of British Columbia and the Division of Hematology, British Columbia Cancer Agency and the University of British Columbia Center for Lymphoid Cancer Research and the Division of Medical Oncology, British Columbia Cancer Agency and the University of British Columbia, Vancouver, Canada
    Ann Oncol 25:2218-23. 2014
    ..The role for HDT/ASCT in chemoresistant HL is less well defined. We evaluated long-term outcomes of relapsed/refractory HL patients whose disease was refractory to secondary chemotherapy preceding HDT/ASCT...
  2. doi D(T)PACE as salvage therapy for aggressive or refractory multiple myeloma
    Alina S Gerrie
    Hematology, University of British Columbia, Vancouver, BC, Canada
    Br J Haematol 161:802-10. 2013
    ..Although the overall response rate of 49% in this poor prognosis cohort is reasonable, the PFS is short, suggesting the best role for D(T)PACE is in bridging to definitive therapy, such as transplantation...
  3. doi Oral fludarabine and rituximab as initial therapy for chronic lymphocytic leukemia or small lymphocytic lymphoma: population-based experience matches clinical trials
    Alina S Gerrie
    Division of Hematology, University of British Columbia, Vancouver, BC, Canada
    Leuk Lymphoma 53:77-82. 2012
    ..FR with oral fludarabine was safely, conveniently and successfully given to community-based patients, irrespective of age, for first-line therapy for CLL/SLL, achieving OS and TFS similar to those in clinical trials...
  4. doi Fludarabine and rituximab for relapsed or refractory hairy cell leukemia
    Alina S Gerrie
    Division of Hematology, University of British Columbia, 2775 Laurel St, Vancouver, BC, Canada
    Blood 119:1988-91. 2012
    ..Five-year progression-free and overall survivals are 89% and 83%, respectively. FR is a safe and effective therapeutic option for relapsed/refractory HCL...
  5. doi Influence of clone and deletion size on outcome in chronic lymphocytic leukemia patients with an isolated deletion 13q in a population-based analysis in British Columbia, Canada
    Steven J T Huang
    Leukemia BMT Program of BC, Vancouver General Hospital and British Columbia Cancer Agency, University of British Columbia, Vancouver, BC, Canada
    Genes Chromosomes Cancer 55:16-24. 2016
    ..2015 Wiley Periodicals, Inc. ..
  6. doi Impact of time from diagnosis to initiation of curative-intent chemotherapy on clinical outcomes in patients with classical Hodgkin lymphoma
    Edward G Brooks
    a Faculty of Medicine, University of British Columbia, Vancouver, BC, Canada
    Leuk Lymphoma 57:872-9. 2016
    ..Nevertheless, clinicians should make every effort possible to initiate curative-intent chemotherapy as soon as a diagnosis of HL is established. ..
  7. doi Population-based characterization of the genetic landscape of chronic lymphocytic leukemia patients referred for cytogenetic testing in British Columbia, Canada: the role of provincial laboratory standardization
    Alina S Gerrie
    Leukemia BMT Program of BC, Vancouver General Hospital and British Columbia Cancer Agency, University of British Columbia, Vancouver, Canada
    Cancer Genet 207:316-25. 2014
    ..Provinces or districts that work together to care for CLL patients can effectively pool data with appropriate laboratory validation to ensure standardization of results. ..
  8. doi Rituximab with high-dose methotrexate in primary central nervous system lymphoma
    Roopesh Kansara
    Centre for Lymphoid Cancer and Department of Medical Oncology, British Columbia Cancer Agency, Vancouver, British Columbia, Canada
    Am J Hematol 90:1149-54. 2015
    ..Prospective randomized trials currently in progress will more definitively estimate the impact of the addition of rituximab to HDMTX-based chemotherapy for PCNSL. Am. J. Hematol. 90:1149-1154, 2015. © 2015 Wiley Periodicals, Inc. ..
  9. doi Allogeneic Hematopoietic Stem Cell Transplantation Is an Effective Salvage Therapy for Patients with Chronic Myeloid Leukemia Presenting with Advanced Disease or Failing Treatment with Tyrosine Kinase Inhibitors
    Anish P Nair
    Leukemia BMT Program of British Columbia, Division of Hematology, Vancouver General Hospital, British Columbia Cancer Agency, and University of British Columbia, Vancouver, British Columbia, Canada
    Biol Blood Marrow Transplant 21:1437-44. 2015
    ..This highlights the ongoing need to try to identify patients earlier, before disease progression, who are destined to fail this treatment to optimize transplantation outcomes...
  10. doi Immunoglobulin heavy chain (IGH@) translocations negatively impact treatment-free survival for chronic lymphocytic leukemia patients who have an isolated deletion 13q abnormality
    Alina S Gerrie
    Division of Hematology, University of British Columbia, Vancouver, Canada
    Cancer Genet 205:523-7. 2012
    ..Knowledge of the t(IGH@) status in CLL is therefore of clinical importance, as del13q patients with concomitant t(IGH@) may not retain the previously expected favorable outcome...
  11. doi Outcome of Patients With Non-Hodgkin Lymphomas With Concurrent MYC and BCL2 Rearrangements Treated With CODOX-M/IVAC With Rituximab Followed by Hematopoietic Stem Cell Transplantation
    Haowei Sun
    Division of Hematology, University of British Columbia, Vancouver, Canada
    Clin Lymphoma Myeloma Leuk 15:341-8. 2015
    ....
  12. doi IgG4-related disease with hypergammaglobulinemic hyperviscosity and retinopathy
    Patrick C W Wong
    Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada
    Eur J Haematol 90:250-6. 2013
    ..Combination therapy with fludarabine and rituximab in IgG4-RD has not previously been reported and can be considered in patients with severe refractory disease...